Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Eyes Top End Of Forecasts

Generics Sales Will Come Close To $720m In 2019

Executive Summary

Hikma has set out updated full-year forecasts in a trading update that indicates its 2019 generics sales will hit the “top end” of its $690m-$720m expectations.

You may also be interested in...



US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

Hikma Starts Seeing Benefits Of Stepping In On US Shortages

Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB149331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel